Berliner Boersenzeitung - US panel replaced under Trump backs new shot for kids

EUR -
AED 4.294295
AFN 80.67101
ALL 97.682021
AMD 448.844558
ANG 2.092317
AOA 1072.100732
ARS 1473.739712
AUD 1.776766
AWG 2.107373
AZN 1.992177
BAM 1.955137
BBD 2.3601
BDT 142.131837
BGN 1.95535
BHD 0.440745
BIF 3438.437284
BMD 1.169139
BND 1.495693
BOB 8.094292
BRL 6.487673
BSD 1.168904
BTN 100.204045
BWP 15.605712
BYN 3.825204
BYR 22915.120971
BZD 2.347904
CAD 1.59888
CDF 3374.135072
CHF 0.931348
CLF 0.029164
CLP 1119.181986
CNY 8.381031
CNH 8.386479
COP 4677.034647
CRC 589.500242
CUC 1.169139
CUP 30.982179
CVE 110.805179
CZK 24.689762
DJF 207.779812
DKK 7.461854
DOP 70.503612
DZD 151.717642
EGP 57.845603
ERN 17.537082
ETB 158.272216
FJD 2.621502
FKP 0.861702
GBP 0.865285
GEL 3.168823
GGP 0.861702
GHS 12.163552
GIP 0.861702
GMD 83.597928
GNF 10120.066085
GTQ 8.978957
GYD 244.547133
HKD 9.177757
HNL 30.807262
HRK 7.533351
HTG 153.418013
HUF 400.227833
IDR 18958.755187
ILS 3.895261
IMP 0.861702
INR 100.371157
IQD 1531.571861
IRR 49235.363231
ISK 142.405567
JEP 0.861702
JMD 186.916661
JOD 0.828966
JPY 172.326976
KES 151.407922
KGS 102.24164
KHR 4701.107625
KMF 492.383265
KPW 1052.26462
KRW 1611.038675
KWD 0.357488
KYD 0.974062
KZT 610.72305
LAK 25171.559311
LBP 104754.839131
LKR 351.510887
LRD 234.997311
LSL 20.729277
LTL 3.452163
LVL 0.707201
LYD 6.30755
MAD 10.525177
MDL 19.789294
MGA 5179.2854
MKD 61.502849
MMK 2453.914221
MNT 4194.40823
MOP 9.451117
MRU 46.419188
MUR 53.172876
MVR 18.009109
MWK 2030.213938
MXN 21.800469
MYR 4.971767
MZN 74.77856
NAD 20.729272
NGN 1790.10397
NIO 42.966292
NOK 11.849901
NPR 160.326672
NZD 1.945581
OMR 0.449532
PAB 1.168909
PEN 4.145811
PGK 4.822406
PHP 66.036513
PKR 332.624323
PLN 4.266714
PYG 9058.930286
QAR 4.256371
RON 5.080731
RSD 117.157108
RUB 91.190148
RWF 1676.545075
SAR 4.384758
SBD 9.734819
SCR 17.066377
SDG 702.072162
SEK 11.170678
SGD 1.496749
SHP 0.91876
SLE 26.30991
SLL 24516.260876
SOS 668.16712
SRD 43.500737
STD 24198.813196
SVC 10.227534
SYP 15201.088778
SZL 20.729263
THB 37.882481
TJS 11.29712
TMT 4.103677
TND 3.39476
TOP 2.738245
TRY 46.964383
TTD 7.941309
TWD 34.16345
TZS 3039.761337
UAH 48.835851
UGX 4189.580317
USD 1.169139
UYU 47.263984
UZS 14804.224604
VES 133.595722
VND 30531.475847
VUV 140.024469
WST 3.214587
XAF 655.729191
XAG 0.030409
XAU 0.000348
XCD 3.159657
XDR 0.813035
XOF 655.306515
XPF 119.331742
YER 282.75665
ZAR 20.94521
ZMK 10523.656585
ZMW 27.058947
ZWL 376.462225
  • CMSC

    0.0900

    22.314

    +0.4%

  • CMSD

    0.0250

    22.285

    +0.11%

  • RBGPF

    0.0000

    69.04

    0%

  • SCS

    0.0400

    10.74

    +0.37%

  • RELX

    0.0300

    53

    +0.06%

  • RIO

    -0.1400

    59.33

    -0.24%

  • GSK

    0.1300

    41.45

    +0.31%

  • NGG

    0.2700

    71.48

    +0.38%

  • BP

    0.1750

    30.4

    +0.58%

  • BTI

    0.7150

    48.215

    +1.48%

  • BCC

    0.7900

    91.02

    +0.87%

  • JRI

    0.0200

    13.13

    +0.15%

  • VOD

    0.0100

    9.85

    +0.1%

  • BCE

    -0.0600

    22.445

    -0.27%

  • RYCEF

    0.1000

    12

    +0.83%

  • AZN

    -0.1200

    73.71

    -0.16%

US panel replaced under Trump backs new shot for kids
US panel replaced under Trump backs new shot for kids / Photo: Elijah Nouvelage - GETTY IMAGES NORTH AMERICA/AFP

US panel replaced under Trump backs new shot for kids

A medical panel appointed by Health Secretary Robert F. Kennedy Jr. voted Thursday to recommend a new antibody treatment against RSV, a common respiratory illness that is the leading cause of hospitalization for infants in the United States.

Text size:

The vote marked the first by the Advisory Committee on Immunization Practices (ACIP) since Kennedy dismissed all members of the influential group of independent experts and replaced them with his own nominees, a move that made this decision a test of the new panel's intentions.

Clesrovimab was recently approved by the Food and Drug Administration as a shot for newborns and young babies experiencing their first respiratory syncytial virus (RSV) season.

Marketed under the name Enflonsia by its manufacturer Merck, it was shown in clinical trials to be safe and effective at significantly reducing RSV infections and hospitalizations among infants.

The ACIP panel was asked to adjudicate the next step after approval -- namely, whether it should now be recommended for infants under eight months old entering their first RSV season who are not already protected by an RSV vaccine administered to their mother during pregnancy.

They voted 5-2 in favor.

The two dissenters were Retsef Levi, a professor of operations management at MIT who has questioned the safety of Covid-19 vaccines, and Vicky Pebsworth, a nurse and member of the anti-vaccine National Vaccine Information Center (NVIC).

"I don't feel this is ready to be administered to all healthy babies. I think we should take a more precautionary approach," said Levi, explaining his "no" vote.

Pebsworth did not offer comments, but the NVIC previously opposed the earlier-approved RSV antibody, nirsevimab.

Kennedy -- who spent decades spreading vaccine misinformation before becoming President Donald Trump's top health official -- abruptly fired all 17 members of the ACIP earlier this month, accusing them of conflicts of interest.

(B.Hartmann--BBZ)